Changes in Hong Kong stocks | Xiansheng Pharmaceutical (02096) rose more than 6% in the intraday period and recently reached a global drug discovery and development cooperation agreement with Schrödinger of the United States

The Zhitong Finance App learned that Xiansheng Pharmaceutical (02096) rose more than 6% in the intraday period. As of press release, it had risen 5.82% to HK$13.26, with a turnover of HK$9.141,000.

According to the news, according to Xiansheng Pharmaceutical's official WeChat account, the company announced that it has recently reached a global drug discovery and development cooperation agreement with Schrödinger of the United States. The two sides will give full play to their respective advantages in drug research and development, focus on unmet clinical needs, and jointly promote innovative drug research and development, relying on Xiansheng Pharmaceutical's expertise in related treatment fields.

With its leading physics-driven computing platform and expertise, Schrödinger will be responsible for computer-aided drug design and optimization in the joint drug discovery phase. After the combined drug discovery phase is completed, Xiansheng Pharmaceutical will lead subsequent pre-clinical research and clinical development. Under the agreement, Schrödinger is entitled to receive milestone payments for cooperative projects in the discovery, development and commercialization stages, as well as tiered royalties based on net product sales.